$Tonix Pharmaceuticals (TNXP.US)$
Finally released?
The new drug application (NDA) for TNX-102 SL for the management of fibromyalgia has been submitted to the FDA, with NDA acceptance expected in December 2024, FDA previously granted fast track designation, and FDA's decision on approval in 2025 is anticipated.
If approved by the FDA, TNX-102 SL will become the first member of a new group of analgesics for fibromyalgia, reappearing after over 15 years as a 🌸new drug🌸 for fibromyalgia treatment.